Basilea

Bio & Pharma SillaJen starts US trial of anti-cancer drug from Basilea

SillaJen Inc. said on Monday it has enrolled the first patient in a US phase 1 trial of an anti-cancer drug BAL0891 licensed from Swiss drugmaker Ba...

Bio & Pharma SillaJen shares jump as exchange maintains listing, allows resumed trade

Shares in South Korea’s scandal-hit biotechnological company SillaJen Inc. soared on Thursday after the local exchange decided to maintain the...